BIP
Chemistry and medicine have been the Smart Specialisation of Lower Silesia since 2015. The study revealed development disproportions depending on subregions or sectors of activity, development potentials or opportunities and threats to innovation development. The study revealed the need to integrate the chemical-pharmaceutical industry, but also to maintain it. The argument for maintaining this Smart Specialisation was the location indexes - higher than 1 - for the criterion of employees and export sales revenue. In the criterion of the number of registered entities (REGON - National Business Registry Number in Poland), the indicator was slightly lower than 1. In its current form, the Lower Silesian Smart Specialisation ‘Chemistry and Medicine’ defines the development area more precisely.
The Lower Silesian Smart Specialisation ‘Chemistry and Medicine’ includes chemical technologies and products, biomedical technologies, procedures and products, and materials engineering. In particular - based on the analysis of the economic and scientific potential and the analysis of trends, the following areas and sub-areas of the specialisation were specified:
1.1.1.
Specialisation encompasses innovation in the area of chemical technologies including the use of biocatalysts (biotechnologies), also on the ‘micro- and nano’ scale (nanotechnologies). Products manufactured on the basis of innovative technologies may already be present on the market. The specialisation encompasses technologies leading in particular to biologically active substances:
- Active Pharmaceutical Ingredient (API) and excipients (including carriers) for the pharmaceutical industry;
- active substances and excipients for cosmetology;
- functional food additives.
1.1.2.
Specialisation encompasses innovation in the area of chemical technologies, including those using biocatalysts (biotechnologies), also at the 'micro- and nano' scale (nanotechnologies). Products manufactured with innovative technologies may already be present on the market. The specialisation encompasses technologies leading to monomers and auxiliary substances used in polymer technologies and laminates.
1.1.3.
Specialisation encompasses innovation in the area of chemical technologies, including those using biocatalysts (biotechnologies), also at the 'micro- and nano' scale (nanotechnologies). Products manufactured with innovative technologies may already be present on the market. Specialisation encompasses technologies leading to high-value chemicals, for example: chemical reagents and standards, diagnostic reagents, pigments, materials with programmable properties, etc. The specialisation does not encompass biologically active substances and excipients used in medicines.
1.1.4.
Specialisation encompasses innovation in the area of chemical technologies, including those using biocatalysts (biotechnologies), also at the 'micro- and nano' scale (nanotechnologies). Products manufactured with innovative technologies may already be present on the market. The specialisation encompasses technologies leading to products that are processed on a large scale, such as e.g. petroleum derivatives, acids and bases, detergents, etc. The specialisation does not encompass monomers and auxiliary substances for the plastics processing industry.
1.2.1.
Specialisation encompasses product innovation involving the launch of new or significantly modified cosmetics, including animal care products.
1.2.2.
Specialisation encompasses product innovations involving the introduction of new or significantly modified household chemical products to the market, used on a small scale and without special restrictions. The group encompasses products such as e.g. washing and rinsing liquids and powders, dishwashing products, cleaning products, including pet care products.
1.2.3.
Specialisation encompasses product innovations involving the introduction of new or significantly modified high-value and technologically advanced chemical intermediates and products with raised performance characteristics, i.e. agrochemicals, biopharmaceuticals and pharmaceuticals, specialised compounds (building blocks), new generation catalysts, etc.
1.2.4.
Specialisation encompasses product innovation involving the introduction of new or significantly modified polymers and laminates to the market.
1.3.1.
Specialisation encompasses product innovation involving the launch of new or substantially modified medicinal and biocidal products, including innovative formulation and formulation.
1.3.2.
Specialisation encompasses product innovation involving the marketing of new or substantially modified medical devices, including diagnostic tests. The specialisation does not encompass the manufacture of exo- and endoprostheses and artificial organs based on mechanotronic systems.
1.3.3.
Specialisation encompasses the development of new diagnostic and therapeutic technologies, particularly in the area of civilisation diseases: heart, cancer, neurodegenerative and rare diseases, including the use of genetic modification and molecular techniques, and their implementation in medical and spa practice.
1.3.4
Specialisation encompasses the development of innovative cellular and other experimental therapies in the field of regenerative medicine, including the use of tissue engineering techniques and biomaterials, and their implementation in medical practice.
1.4.1.
Specialisation encompasses product innovation involving the introduction of new or significantly altered materials on the market with programmed properties and responsive to changes in external factors (with the exception of detectors and sensors).
1.4.2.
Specialisation encompasses product innovation involving the marketing of new or significantly altered materials for the reactive component of detectors and sensors and diagnostic tests, in particular mimetic systems or nanostructures.
1.4.3.
Specialisation encompasses product innovations involving the marketing of new or significantly modified micro- and macro-scale insulation materials, such as aerogels.